HER2 Is a Viable Target in Biliary Tract Cancer

There is increasing evidence supporting routine performance of next-generation sequencing to identify targetable genomic abnormalities in biliary cancers. Regulatory approval has recently been achieved for agents targeting the fibroblast growth factor receptor (FGFR) and isocitrate dehydrogenase 1 (IDH-1) pathways.

Investigators now report results from a cohort of patients with HER2-positive advanced biliary cancers in MyPathway, an open-label, phase 2, basket trial of patients with advanced solid tumors and potentially targetable molecular alterations. Patients with previously treated advanced biliary cancer who tested positive for HER2 based on immunohistochemistry, fluorescent in situ hybridization testing, or next-generation sequencing a…